IDEAYA's Cancer Candidate Shows Early Tumor Modulation

  • IDEAYA Biosciences Inc IDYA reported additional clinical pharmacodynamic (PD) data from translational analysis of circulating tumor DNA (ctDNA) and molecular responses.
  • The IDE397 ctDNA molecular response data demonstrate target engagement and a dose-dependent tumor pharmacodynamic modulation. 
  • Molecular responses based on ctDNA were evaluable for thirteen patients with liquid biopsy samples available at baseline and after the first treatment cycle. 
  • Related: Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor Collaboration With GSK.
  • Significantly, ctDNA molecular responses were observed in three of four evaluable patients treated with IDE397 at higher doses in Cohorts 5 and 6 and in 2/2 NSCLC evaluable patients. 
  • This indicates a preliminary signal of clinical activity and is consistent with preclinical in vivo observations in patient-derived xenograft models.  
  • IDEAYA has delivered an IDE397 option data package to GSK Plc GSK comprising preclinical and clinical data from the IDE397 monotherapy dose escalation Phase 1 study.
  • IDEAYA Biosciences entered into a clinical trial collaboration and supply agreement with Amgen Inc AMGN to evaluate IDE397 with Amgen's AMG 193 in the Phase 1 trial. 
  • Price Action: IDYA shares are down 2.04% at $14.90 during the market session on the last check Wednesday.
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs